12th ICML Highlights in Lymphoma

Dr. Peter Borchmann discusses how discrimination of an early unfavorable risk group has significant impact on treatment outcome in early stage Hodgkin lymphoma.
Dr. Robert Chen discusses the findings from his clinical trial with Brentuximab vedotin and reduced-intensity allogeneic transplant in relapsed or refractory Hodgkin lymphoma.
Dr. Andrew Evens discusses clinical trials and comorbidities specific to the treatment of Hodgkin lymphoma in the elderly.
Dr. Mary Gospodarowicz discusses if radiation therapy should be a part of the standard therapy for stage 1 and 2 Hodgkin lymphoma.
Prof. Tim Illidge discusses the role of radiation therapy in the treatment of Hodgkin lymphoma.
Dr. Peter Johnson discusses the results from the international response adapted therapy in advanced HL (RATHL) study, responses and chemotherapy dose adjustment determined by PET-CT imaging.
Dr. James Armitage discusses the latest updates in the treatment of Hodgkin lymphoma.
Dr. James Armitage provides an overview of the 12th International Conference on Malignant Lymphoma.

Results 1 - 8 of 8

MediCom Worldwide, Inc. would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support. To better serve the needs of our audience, ManagingHodgkinLymphoma.com is now ManagingLymphoma.com

©2019 MediCom Worldwide, Inc. All rights reserved